Many pharmaceutical companies are looking to develop and market the now highly popular GLP-1 drugs, which help treat diabetes, help patients lose weight, and reduce their risk of a range of conditions linked to obesity. The drugmakers that lead this market over the next decade could reap substantial financial benefits for themselves and their shareholders. But what if companies outside of the pharmaceutical industry benefit as well? One excellent candidate to do so is DexCom (NASDAQ: DXCM). Let's conside ...

Core Insights - DexCom, Inc. (NASDAQ:DXCM) is a leading company in the medical device sector, focusing on continuous glucose monitoring (CGM) systems for diabetes management, competing with firms like Abbott Laboratories and Medtronic [1] Stock Performance - Over the past 30 days, DXCM has experienced a modest gain of 1.16%, indicating positive investor interest, although there was a recent decline of 3.43% over the last 10 days, which may present a strategic entry point for investors [2] Growth Potential - The company has a projected growth potential of 22.52%, reflecting strong fundamentals and market position, which are essential for investors seeking significant returns [3] Financial Health - DexCom holds a Piotroski Score of 8, indicating robust financial health in terms of profitability, leverage, liquidity, and operating efficiency, making it an appealing option for long-term investors [4][6] Target Price - The target price for DXCM is set at $85.82, serving as a benchmark for investors and reflecting the stock's potential for growth driven by solid fundamentals and market dynamics [5]

Core Insights - Dexcom achieved revenues of $4.66 billion in 2025, reflecting a 16% increase from approximately $4 billion in 2024, with Q4 2025 earnings of $1.26 billion indicating a 12.6% year-over-year rise [1] - The 2026 revenue outlook is projected to be between $5.16 billion and $5.25 billion, which, while showing healthy double-digit growth of 11%–13%, is below analysts' expectations of $5.24 billion [2] Financial Performance - Q4 2025 earnings of $1.26 billion represent a 12.6% increase year-over-year, with an organic growth rate of 12% [1] - The company's market capitalization stands at $25.38 billion, with a slight decline in share price to $64.92 at market open on 13 February, before rallying over 8% by mid-morning [3] Strategic Initiatives - The company aims to enhance awareness of its new G7 15-day device launched in December 2025 and improve customer experience for users of its CGM systems [4] - Dexcom plans to launch Smart Basal, a personalized dosing module for managing type 2 diabetes, which is expected to simplify workflows and improve outcomes for users [5] - The company is focused on expanding its international market presence by raising awareness and increasing access to CGM technology [5] Market Position - In 2025, Dexcom held the second largest CGM market share in the US at 44.7%, trailing Abbott, which has a 48.5% share [6] - Dexcom's market share in regions such as Europe, Asia Pacific, and the Middle East & Africa is significantly lower compared to Abbott [6]

Core Insights - DexCom Inc (NASDAQ:DXCM) is recognized as one of the top 12 medical device stocks favored by hedge funds, with a strong bullish sentiment reflected in analyst ratings [1] - The company reported fourth-quarter results with U.S. revenues of $892 million and international revenues of $368 million, achieving year-over-year growth of 11% and 18% respectively, surpassing consensus estimates by nearly 2 percentage points [2] - For FY 2025, management anticipates an adjusted gross margin of approximately 61% and an adjusted operating margin of around 20%-21%, with projected revenues for 2026 between $5.16 billion and $5.25 billion [3] Company Overview - DexCom Inc specializes in continuous glucose monitoring (CGM) systems that assist in managing diabetes and metabolic conditions by providing real-time glucose level tracking [4]

Group 1 - DexCom, Inc. reported preliminary, unaudited Q4 2025 results with total revenue of approximately $1.260 billion, reflecting a 13% year-over-year increase [1][2] - US revenue for Q4 2025 is projected to be around $892 million, showing an 11% growth compared to Q4 2024 [1][2] - The company launched its latest sensor technology, the G7 15 Day system, contributing to its positive performance and growth outlook [2] Group 2 - For 2026, DexCom expects total revenue between $5.16 billion and $5.25 billion, indicating an anticipated growth of approximately 11%-13% over 2025 [3] - The growth outlook is supported by factors such as increased awareness of continuous glucose monitoring (CGM) among diabetes patients, the rollout of the Stelo system, and further international expansion [3] - DexCom focuses on the design, development, and commercialization of continuous glucose monitoring systems, positioning itself as a key player in the medical device industry [4]

Core Insights - The article highlights significant structural changes in retirement and healthcare financing in the U.S. by 2026, which will impact consumer payment methods for care and competition among medical device companies [1] Policy Changes - The IRS has increased Health Savings Account (HSA) contribution limits for 2026 to $4,400 for individuals and $8,750 for families, up from $4,300 and $8,550 in 2025 respectively [2] - The age-55 "catch-up" contribution remains at $1,000, reflecting cost-of-living adjustments aimed at preserving the tax-advantaged nature of HSAs [3] - Medicare Part B premiums are rising to $202.90 per month, an increase of nearly $18 from 2025, with the Part B deductible increasing to $283 [4] Implications of HSA and Medicare Changes - The rising HSA limits make HSAs more attractive for managing out-of-pocket healthcare costs, while higher Medicare premiums may lead to increased enrollment in Medicare plans and ancillary services [5] - HSAs can be used for both current medical costs and qualified medical device expenses, allowing consumers to save more tax-free dollars for durable medical equipment [6] - Higher premiums may increase demand for technologies that improve disease self-management and prevent costly complications, influencing total care costs [7] Companies Positioned to Benefit - DexCom, ResMed, and Masimo are identified as companies likely to benefit from these trends due to their focus on markets where out-of-pocket costs and reimbursement policies significantly affect adoption [8] - DexCom's continuous glucose monitoring (CGM) systems may see increased adoption as higher HSA limits help patients manage diabetes costs [9] - ResMed's devices for sleep and respiratory care align with the aging Medicare demographic and rising out-of-pocket care needs [9] - Masimo's monitoring tools support preventive care, which becomes more relevant as Medicare premiums rise [9] Company-Specific Insights - DexCom is a leader in CGM systems, providing real-time glucose data that aids in insulin delivery and lifestyle management, with a focus on expanding Medicare coverage for CGM devices [10][11] - Higher HSA limits allow diabetes patients to allocate more pre-tax savings for CGM systems, reducing financial barriers to adoption [12] - ResMed specializes in devices for sleep-disordered breathing, with rising premiums incentivizing seniors to use HSAs for optimal therapy devices [15][16] - Masimo develops non-invasive monitoring systems, with increased demand for preventive monitoring as Medicare beneficiaries face higher premiums [18][19]

Core Viewpoint - DexCom, Inc. is a leading medical device company specializing in continuous glucose monitoring systems, with a market cap of $24.8 billion, indicating its significant influence in the diabetes care market [1][2]. Company Overview - DexCom designs and commercializes CGM systems, including a small implantable device for measuring glucose levels and an external receiver for data transmission [1]. - The company is categorized as a large-cap stock, reflecting its substantial market presence and dominance in the medical devices industry [2]. Market Performance - DexCom's stock has experienced a decline of 30.9% from its 52-week high of $93.25, reached on February 18, and has underperformed the S&P 500 Index, which gained 6.5% over the same period [3]. - Over the past six months, DexCom shares fell by 24.6%, and over the past year, they decreased by 18.7%, significantly lagging behind the S&P 500's gains of 15.1% and 12.9%, respectively [4]. Technical Analysis - The stock has been trading below its 200-day moving average since early August, indicating a bearish trend, although it recently traded above the 50-day moving average [4]. Challenges and Concerns - The company's underperformance is attributed to an FDA warning letter regarding manufacturing issues, trade war concerns with China affecting supply chains, and higher scrap rates along with sensor deployment issues [5]. - Management is optimistic about improvements due to new quality controls and shipping methods [5]. Financial Results - In Q3, DexCom reported an adjusted EPS of $0.61, exceeding Wall Street's expectation of $0.57, and revenue of $1.21 billion, surpassing the forecast of $1.18 billion [6]. - The company anticipates full-year revenue between $4.6 billion and $4.7 billion [6].

Core Viewpoint - Labaton Keller Sucharow LLP has filed a securities class action lawsuit against DexCom, Inc. and certain executives, alleging misleading statements regarding the reliability and safety of their continuous glucose monitoring systems [1][4]. Summary by Sections Lawsuit Details - The lawsuit was filed on November 25, 2025, on behalf of the Boston Retirement System against DexCom and its executives, asserting claims under the Securities Exchange Act of 1934 [1]. - The class period for the lawsuit is defined as January 8, 2024, to September 17, 2025 [1]. Allegations - The complaint alleges that DexCom made unauthorized design changes to its CGM products, which rendered them less reliable and posed health risks to users [4]. - It is claimed that these undisclosed issues led to increased regulatory scrutiny and negatively impacted the company's sales and public statements regarding product reliability [4]. Impact on Stock Price - Following disclosures about the accuracy problems of DexCom's CGM devices, the company's stock price fell by $8.99 per share, or 11.8%, closing at $67.45 on September 19, 2025 [5]. Legal Representation - The Boston Retirement System is represented by Labaton Keller Sucharow LLP, which has a strong reputation in securities litigation and manages over $4.5 trillion in assets [8].

Core Insights - DexCom Inc. is recognized as a strong stock within the QQQ index, despite recent price target reductions by analysts [1][2] - The company reported a significant year-over-year revenue increase, but faced challenges with gross margins [3][4] Financial Performance - DexCom achieved $1.21 billion in worldwide revenue for Q3 2025, reflecting a 22% increase year-over-year and 20% organic growth [3] - The company reported a net income of $242.5 million, translating to an earnings per share (EPS) of $0.61, marking the highest quarterly EPS in its history [3] Margin and Guidance Adjustments - Despite record revenue, DexCom's gross profit margin declined to 61.3% from 63% in Q3 2024, attributed to higher-than-expected scrap rates in manufacturing [4] - The company revised its 2025 non-GAAP gross profit margin guidance to approximately 61% while raising its overall revenue guidance to a range of $4.630 to $4.650 billion [4] Analyst Ratings - Morgan Stanley reduced its price target for DexCom to $63 from $89 but maintained an Overweight rating [1] - Truist lowered its price target to $82 from $94, citing a modest earnings beat and weaker-than-expected gross margins [2]

Core Viewpoint - Carillon Tower Advisers' "Carillon Eagle Mid Cap Growth Fund" reported a continued rally in equity markets during Q3 2025, driven by AI enthusiasm, limited inflationary effects from tariffs, and expectations for interest rate cuts from the U.S. Federal Reserve [1] Market Performance - The Russell Midcap Growth Index increased by 2.78%, while the Russell Midcap® Value Index outperformed with a gain of 6.16% during the same quarter [1] Sector Insights - The investor letter provided detailed insights on various sectors including Cyclicals, Healthcare, Information Technology, Financials, and Consumer sectors [1] Company Focus: DexCom, Inc. - DexCom, Inc. (NASDAQ:DXCM) is highlighted as a key stock, known for its continuous glucose monitoring systems, but has faced challenges including a one-month return of -10.14% and a 52-week loss of 20.18% [2][3] - As of November 24, 2025, DexCom's stock closed at $62.21, with a market capitalization of $24.396 billion [2] Financial Performance of DexCom - DexCom reported global revenue of $1.21 billion in Q3 2025, an increase from $994 million in Q3 2024, indicating a positive revenue trend despite recent challenges [4] Concerns and Market Position - There are concerns regarding accuracy issues with DexCom's latest G7 continuous glucose monitor, which may impact its brand and market share [3] - Despite the potential of DexCom as an investment, the company is viewed as having less upside compared to certain AI stocks [4]